The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Efficacy and safety of Ayurvedic herbs in diarrhoea-predominant irritable bowel syndrome: A randomised controlled crossover trial
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“extracts such as Curcuma xanthorrhiza, Fumaria officinalis, and various Ayurvedic formulations have not shown significant clinical benefit”
From Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines (2026) · cites this paper as [87]
In the citing paper
“The compound showed no greater improvement in IBS-D symptoms than placebo [87].”
From Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines (2026) · cites this paper as [87]
In the citing paper
“In the other study by Lauche et al. [27], which found non-significant effects compared to placebo, the sample size was limited and there was a high drop-out rate (11 out of 32 participants) and consequent loss of statistical power. Patient blinding was also unsuccessful in that study [27], as the majority of the patients correctly identified the active intervention or placebo during the trial.”
From A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS) (2018) · cites this paper as [27]
In the citing paper
“Of the five clinical trials reviewed, three reported positive and significant effects for curcumin-containing products [24,26,28], while two [25,27] found no significant effects compared to placebo and advised against monotherapy with curcumin.”
From A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS) (2018) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Lovell, R. M., & Ford, A. C. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.02.029 · Cited by 2,155
FRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708
Patrick, D. L., Drossman, D. A., Frederick, I. O., Dicesare, J., & Puder, K. L. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018831127942 · Cited by 761
Design of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Tack, J., Crowell, M. D., Gwee, K. A., Ke, M., Schmulson, M. J., Whitehead, W. E., & Spiegel, B. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.010 · Cited by 550
Design of Treatment Trials for Functional Gastrointestinal Disorders
Irvine, E. J., Whitehead, W. E., Chey, W. D., Matsueda, K., Shaw, M., Talley, N. J., & Veldhuyzen van Zanten, S. J. O. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.058 · Cited by 286
Severity in Irritable Bowel Syndrome: A Rome Foundation Working Team Report
Drossman, D. A., Chang, L., Bellamy, N., Gallo-Torres, H. E., Lembo, A., Mearin, F., Norton, N. J., & Whorwell, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.201 · Cited by 226
Furst, D. E., Venkatraman, M. M., McGann, M., Manohar, P. R., Booth-LaForce, C., Sarin, R., Sekar, P. G., Raveendran, K. G., Mahapatra, A., Gopinath, J., et al. (2011) · JCR: Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e31821c0310 · Cited by 79
Research works printed but not linked: 21
- Quigley, 2012, A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome, J Clin Gastroenterol, 46, 356, 10.1097/MCG.0b013e318247157c · DOI
- Drossman, 2006, Rome III: the new criteria, Chin J Dig Dis, 7, 181, 10.1111/j.1443-9573.2006.00265.x · DOI
- Drossman, 2006, New standard for functional gastrointestinal disorders, J Gastrointest Liver Dis, 15, 237
- Longstreth, 2006, Functional bowel disorders, Gastroenterology, 130, 1480, 10.1053/j.gastro.2005.11.061 · DOI · Paper page
- Bensoussan, 1998, Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial, JAMA, 280, 1585, 10.1001/jama.280.18.1585 · DOI · Paper page
- Wu, 2010, Complementary and alternative medicine modalities for the treatment of irritable bowel syndrome: facts or myths, Gastroenterol Hepatol, 6, 705
- Hilsden, 2003, Complementary and alternative medicine use by Canadian patients with inflammatory bowel disease: results from a national survey, Am J Gastroenterol, 98, 1563, 10.1111/j.1572-0241.2003.07519.x · DOI
- Langhorst, 2005, Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey, Inflamm Bowel Dis, 11, 287, 10.1097/01.MIB.0000160771.71328.6c · DOI
- van Tilburg, 2008, Complementary and alternative medicine use and cost in functional bowel disorders: a six month prospective study in a large HMO, BMC Complement Altern Med, 8, 46, 10.1186/1472-6882-8-46 · DOI
- Vlieger, 2008, Use of complementary and alternative medicine by pediatric patients with functional and organic gastrointestinal diseases: results from a multicenter survey, Pediatrics, 122, e446, 10.1542/peds.2008-0266 · DOI
- Leung, 2006, Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial, Am J Gastroenterol, 101, 1574, 10.1111/j.1572-0241.2006.00576.x · DOI
- Layer, 2011, Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management, Z Gastroenterol, 49, 237, 10.1055/s-0029-1245976 · DOI
- Bushnell, 2006, Performance of the EQ-5D in patients with irritable bowel syndrome, Value Health, 9, 90, 10.1111/j.1524-4733.2006.00086.x · DOI
- Wang, 2012, Validation of the EQ-5D in a general population sample in urban China, Qual Life Res, 21, 155, 10.1007/s11136-011-9915-6 · DOI
- Drossman, 2000, Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire, Am J Gastroenterol, 95, 999, 10.1111/j.1572-0241.2000.01941.x · DOI · Paper page
- Mangel, 1998, Adequate relief as an endpoint in clinical trials in irritable bowel syndrome, J Int Med Res, 26, 76, 10.1177/030006059802600203 · DOI
- Yadav, 1989, Irritable bowel syndrome: therapeutic evaluation of indigenous drugs, Indian J Med Res, 90, 496
- Brinkhaus, 2005, Herbal medicine with curcuma and fumitory in the treatment of irritable bowel syndrome: a randomized, placebo-controlled, double-blind clinical trial, Scand J Gastroenterol, 40, 936, 10.1080/00365520510023134 · DOI · Paper page
- Hentschel, 1996, Complementary medicine in irritable bowel syndrome a randomised double blind, placebo-controlled trial, Dig Dis Week, A380
- Ottillinger, 2013, STW 5 (Iberogast(R))—a safe and effective standard in the treatment of functional gastrointestinal disorders, Wien Med Wochenschr, 163, 65, 10.1007/s10354-012-0169-x · DOI
- Jagetia, 2002, The evaluation of the radioprotective effect of Triphala (an ayurvedic rejuvenating drug) in the mice exposed to gamma-radiation, Phytomedicine, 9, 99, 10.1078/0944-7113-00095 · DOI
Cited by
A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS)
Ng, Q., Soh, A., Loke, W., Venkatanarayanan, N., Lim, D., & Yeo, W.-S. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7100298 · Cited by 95
Bogdan, C., Iurian, S., Tomuta, I., & Moldovan, M. L. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s128470 · Cited by 69
A systematic review of the efficacy and safety of turmeric in the treatment of digestive disorders
Thavorn, K., Wolfe, D., Faust, L., Shorr, R., Akkawi, M., Isaranuwatchai, W., Klinger, C., Chai‐Adisaksopa, C., Tanvejsilp, P., Nochaiwong, S., et al. (2024) · Phytotherapy Research · doi:10.1002/ptr.8189 · Cited by 11
Pastras, P., Aggeletopoulou, I., Bali, M., & Triantos, C. (2026) · Nutrients · doi:10.3390/nu18020183 · Cited by 1
Metadata
- Authors
- Lauche, R., Kumar, S., Hallmann, J., Lüdtke, R., Rampp, T., Dobos, G., & Langhorst, J.
- Venue
- Complementary Therapies in Medicine
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 26
- Pages
- 171-177
- ISSN
- 0965-2299
- Cited by
- 37
- References
- 7
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
